Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation

Diabetes, Obesity and Metabolism

Volumn 11, Issue 10, 2009, Pages 953-965

  Ma, X ^a   Hui, H ^b   Liu, Z ^c   He, G ^a   Hu, J ^a   Meng, J ^a   Guan, L ^a   Luo, X ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Toxicology   (China)

Author keywords

Diabetes; GLP 1; Insulin sensitivity; Obesity; Polymer; Prodrug

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG RELEASE; FEMALE; FOOD INTAKE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HYPERGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RAT; SINGLE DRUG DOSE; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCAGON-LIKE PEPTIDE 1; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICE; MICE, INBRED BALB C; POLYMERS; PRODRUGS;

EID: 70349779631     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01070.x     Document Type: Article

References (48)

1. Drucker DJ. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
2. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
3. Farilla L, Hui H, Bertolotto C. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002, 143:4397-4408.
4. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003, 144:5145-5148.
5. Turton MD, O'Shea D, Gunn I. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
6. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
7. During MJ, Cao L, Zuzga DS. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179.
8. Meier JJ, Nauck MA, Kranz D. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004, 53:654-662.
9. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
10. Hui H, Zhao X, Perfetti R. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev 2005, 21:313-331.
11. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
12. Vilsboll T, Zdravkovic M, Le-Thi T. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30:1608-1610.
13. Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008, 134:1137-1147.
14. Knudsen LB, Nielsen PF, Huusfeldt PO. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000, 43:1664-1669.
15. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004, 53:2492-2500.
16. Grouzmann E, Monod M, Landis BN, Lacroix JS. Adverse effects of incretin therapy for type 2 diabetes. JAMA 2007, 298:1759-1760.
17. Oliyai R, Stella VJ. Prodrugs of peptides and proteins for improved formulation and delivery. Annu Rev Pharmacol Toxicol 1993, 33:521-544.
18. Zhao H, Yang K, Martinez A. Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins. Bioconjug Chem 2006, 17:341-351.
19. Roseeuw E, Coessens V, Schacht E, Vrooman B, Domurado D, Marchal G. Polymeric prodrugs of antibiotics with improved efficiency. J Mater Sci Mater Med 1999, 10:743-746.
20. Cavallaro G, Pitarresi G, Licciardi M, Giammona G. Polymeric prodrug for release of an antitumoral agent by specific enzymes. Bioconjug Chem 2001, 12:143-151.
21. Tanihara M, Suzuki Y, Nishimura Y, Suzuki K, Kakimaru Y. Thrombin-sensitive peptide linkers for biological signal-responsive drug release systems. Peptides 1998, 19:421-425.
22. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967, 16:35-39.
23. Lee S, Youn YS, Lee SH, Byun Y, Lee KC. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 2006, 49:1608-1611.
24. Claret M, Corominola H, Canals I. S 23521 decreases food intake and body weight gain in diet-induced obese rats. Obes Res 2004, 12:1596-1603.
25. Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ. Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 2000, 275:34471-34477.
26. Rabinovitch A, Gutzeit A, Renold AE, Cerasi E. Insulin secretion in the spiny mouse (Acomys cahirinus). Dose and time kinetic studies with glucose in vivo and in vitro. Diabetes 1975, 24:1094-1100.
27. Sinkula AA, Yalkowsky SH. Rationale for design of biologically reversible drug derivatives: prodrugs. J Pharm Sci 1975, 64:181-210.
28. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
29. Fridolf T, Ahren B. GLP-1(7-36) amide stimulates insulin secretion in rat islets: studies on the mode of action. Diabetes Res 1991, 16:185-191.
30. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001, 50:1004-1011.
31. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978, 200:21-27.
32. Young AA, Gedulin BR, Bhavsar S. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48:1026-1034.
33. Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 2002, 146:863-869.
34. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002, 45:1263-1273.
35. Ahren B, Winzell MS, Wierup N, Sundler F, Burkey B, Hughes TE. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. Regul Pept 2007, 143:97-103.
36. Hollenbeck CB, Chen N, Chen YD, Reaven GM. Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes 1984, 33:460-463.
37. Gedulin BR, Nikoulina SE, Smith PA. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005, 146:2069-2076.
38. Pickavance LC, Wilding JP. Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker diabetic fatty rat. Diabetes Obes Metab 2007, 9:114-120.
39. Gokcel A, Baltali M, Tarim E. Detection of insulin resistance in Turkish adults: a hospital-based study. Diabetes Obes Metab 2003, 5:126-130.
40. Yokoyama H, Emoto M, Fujiwara S. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 2003, 26:2426-2432.
41. Bonora E, Targher G, Alberiche M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63.
42. Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab 2001, 86:4615-4617.
43. Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002, 87:3768-3773.
44. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28:187-218.
45. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004, 36:804-810.
46. Rolin B, Larsen MO, Gotfredsen CF. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002, 283:E745-E752.
47. D'Amico E, Hui H, Khoury N, Di MU, Perfetti R. Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs. J Mol Endocrinol 2005, 34:377-390.
48. Stoffers DA, Kieffer TJ, Hussain MA. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000, 49:741-748.